SAN CARLOS, Calif., Sept. 13, 2018 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced an agreement with Bristol-Myers Squibb to use Natera’s Signatera™ custom circulating tumor DNA (ctDNA) assay in a Phase 2 study in the adjuvant non-small cell lung cancer (NSCLC) setting. The study will use …
Tag Archives: Natera
September, 2018
August, 2018
-
16 August
Natera and Fox Chase Cancer Center to Collaborate to Assess the Signatera Customized ctDNA Assay for Monitoring Kidney Cancer
SAN CARLOS, Calif., Aug. 15, 2018 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, has partnered with Fox Chase Cancer Center, one of the leading cancer centers in the United States, to assess the company’s Signatera™ (Research-Use Only) customized circulating tumor DNA (ctDNA) assay for …
October, 2015
-
28 October
Natera’s mmPCR Technology Successfully Identified breast Cancer in Study
SAN CARLOS, Calif., Oct. 28, 2015 /PRNewswire/ — Natera, Inc., (NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced a study published in the October 2015 issue of Translational Oncology showing that Natera’s massively multiplexed PCR (mmPCR) technology and proprietary analytic methodologies can detect …